CryoCor concludes enrollment for atrial fibrillation study
Cryoablation technology device developer CryoCor said that it has completed the enrollment of its clinical study for the treatment of atrial fibrillation, which includes more than 170 patients. A 12-month follow up will take place for each patient.

The San Diego-based firm manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias.

Ed Brennan, CEO of CryoCor said the company anticipates U.S. approval of its technology for the treatment of atrial fibrillation in 2009.